Estimaciones de analistas de Wall Street para Pfizer Inc. (PFE): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.79 | ||
| 2026-08-04 | $0.77 | $0.68 | +12.9% |
| 2026-05-05 | $0.75 | $0.72 | +3.9% |
| 2026-02-03 | $0.66 | $0.57 | +16.4% |
| 2025-11-04 | $0.87 | $0.63 | +37.4% |
| 2025-08-05 | $0.78 | $0.58 | +34.5% |
| 2025-04-29 | $0.92 | $0.67 | +38.1% |
| 2025-02-04 | $0.63 | $0.47 | +33.6% |
Ratios de valoración
| Ratio P/E | 35.87 |
| Precio / Valor contable | 1.82 |
| EV / EBITDA | 17.33 |
| Rentabilidad por dividendo | 6.34% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $52.82B | $52.55B | $53.65B | $41.17B | $41.65B | $81.29B | $100.33B | $59.55B | $63.63B | $62.58B |
| Coste de Ventas | $15.95B | $15.78B | $16.01B | $12.62B | $11.77B | $34.41B | $38.24B | $29.21B | $21.78B | $18.57B |
| Beneficio Bruto | $36.87B | $36.77B | $37.64B | $28.55B | $29.88B | $46.88B | $62.09B | $30.34B | $41.85B | $44.01B |
| I+D | $7.84B | $7.64B | $7.97B | $8.36B | $9.39B | $13.83B | $11.43B | $10.58B | $10.74B | $11.98B |
| Generales y Administrativos | $14.76B | $14.73B | $14.38B | $12.67B | $11.40B | $12.25B | $13.12B | $14.47B | $14.73B | $13.35B |
| Gastos Operativos | $22.60B | $22.38B | $22.35B | $21.04B | $20.80B | $26.08B | $24.54B | $25.05B | $25.36B | $28.58B |
| Beneficio Operativo | $14.27B | $14.39B | $15.29B | $7.51B | $9.09B | $20.79B | $37.55B | $5.29B | $16.48B | $15.44B |
| EBITDA | $15.29B | $19.84B | $19.59B | $18.85B | $13.17B | $30.79B | $41.03B | $9.56B | $18.13B | $15.10B |
| Gastos por Intereses | $1.19B | $1.27B | $1.32B | $1.57B | $1.45B | $1.29B | $1.24B | $2.21B | $3.09B | $2.67B |
| Beneficio Antes de Impuestos | $8.35B | $12.30B | $11.88B | $11.48B | $7.04B | $24.31B | $34.73B | $1.06B | $8.02B | $7.52B |
| Impuestos | $1.12B | -$9.05B | $706.0M | $618.0M | $370.0M | $1.85B | $3.33B | -$1.11B | -$28.0M | -$266.0M |
| Beneficio Neto | $7.21B | $21.30B | $11.15B | $16.27B | $9.16B | $22.15B | $31.36B | $2.13B | $8.02B | $7.77B |
| BPA | $1.18 | $3.57 | $1.90 | $2.92 | $1.65 | $3.95 | $5.59 | $0.38 | $1.42 | $1.36 |
| BPA Diluido | $1.17 | $3.52 | $1.87 | $2.87 | $1.63 | $3.88 | $5.47 | $0.37 | $1.41 | $1.36 |
| Acciones en Circulación (Diluidas) | $6.16B | $6.06B | $5.98B | $5.67B | $5.63B | $5.71B | $5.73B | $5.71B | $5.70B | $5.69B |
Precio
| Precio | $27.46 |
| Capitalización | $156.5B |
| Bolsa | NYSE |
| País | US |
Empresas relacionadas: AMGN · BMY · BSX · DHR · GILD · GSK · MRK
Explorar sector: Healthcare · Drug Manufacturers - General
Más secciones de PFE: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones